Powered by 
Google Übersetzer
Google Übersetzer
14 July 2025
N4 Pharma plc
("N4 Pharma" or the "Company")
Investor Webinar
N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce that Nigel Theobald, Chief Executive Officer, will provide a strategic update on the Company's ongoing development of Nuvec® as a delivery system for RNA therapeutics on Tuesday, 22 July 2025 at 10.00 am via the Investor Meet Company Platform.
Nigel will be joined by members of the Senior Leadership Team, including Dr Mark Edbrooke, Head of Strategy, who will present on The RNA Therapeutics Revolution, and Dr Fiona McLaughlin, Head of Research and Development, who will present on Established Delivery Platforms and the Key Benefits of Nuvec®.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00 am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet N4 Pharma plc via:
https://www.investormeetcompany.com/n4-pharma-plc/register-investor
Investors who already follow N4 Pharma plc on the Investor Meet Company platform will automatically be invited.
- Ends -
For more information please contact:
|
N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director
Submit your questions directly to the management team via the N4 Pharma Investor Hub
|
Via N4 Pharma Investor Hub: investors.n4pharma.com
|
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) |
Tel: +44 (0)20 3470 0470 |
|
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope |
Tel: +44 (0)20 3657 0050 |
|
Northstar Communications Limited Investor Relations Sarah Hollins |
Tel: +44 (0)113 730 3896
|
About N4 Pharma
N4 Pharma is a pre-clinical biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with commercial partners.
N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.
For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.
